Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
eLife Sciences Publications Ltd
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/355bde8c5cd74382bd903bb187245f09 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:355bde8c5cd74382bd903bb187245f09 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:355bde8c5cd74382bd903bb187245f092021-11-23T12:38:36ZCross-reactive antibodies after SARS-CoV-2 infection and vaccination10.7554/eLife.703302050-084Xe70330https://doaj.org/article/355bde8c5cd74382bd903bb187245f092021-11-01T00:00:00Zhttps://elifesciences.org/articles/70330https://doaj.org/toc/2050-084XCurrent SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11- to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2- to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.Marloes GrobbenKarlijn van der StratenPhilip JM BrouwerMitch BrinkkemperPauline MaisonnasseNathalie Dereuddre-BosquetBrent AppelmanAH Ayesha LavellLonneke A van VughtJudith A BurgerMeliawati PonimanMelissa OomenDirk EgginkTom PL BijlHugo DG van WilligenElke WynbergBas J VerkaikOrlane JA FigaroaPeter J de VriesTessel M BoertienAmsterdam UMC COVID-19 S3/HCW study groupMarije K BomersJonne J SikkensRoger Le GrandMenno D de JongMaria PrinsAmy W ChungGodelieve J de BreeRogier W SandersMarit J van GilseLife Sciences Publications LtdarticleantibodiesSARS-CoV-2coronaviruscross-reactivityvaccineCOVID-19MedicineRScienceQBiology (General)QH301-705.5ENeLife, Vol 10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
antibodies SARS-CoV-2 coronavirus cross-reactivity vaccine COVID-19 Medicine R Science Q Biology (General) QH301-705.5 |
| spellingShingle |
antibodies SARS-CoV-2 coronavirus cross-reactivity vaccine COVID-19 Medicine R Science Q Biology (General) QH301-705.5 Marloes Grobben Karlijn van der Straten Philip JM Brouwer Mitch Brinkkemper Pauline Maisonnasse Nathalie Dereuddre-Bosquet Brent Appelman AH Ayesha Lavell Lonneke A van Vught Judith A Burger Meliawati Poniman Melissa Oomen Dirk Eggink Tom PL Bijl Hugo DG van Willigen Elke Wynberg Bas J Verkaik Orlane JA Figaroa Peter J de Vries Tessel M Boertien Amsterdam UMC COVID-19 S3/HCW study group Marije K Bomers Jonne J Sikkens Roger Le Grand Menno D de Jong Maria Prins Amy W Chung Godelieve J de Bree Rogier W Sanders Marit J van Gils Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| description |
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11- to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2- to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine. |
| format |
article |
| author |
Marloes Grobben Karlijn van der Straten Philip JM Brouwer Mitch Brinkkemper Pauline Maisonnasse Nathalie Dereuddre-Bosquet Brent Appelman AH Ayesha Lavell Lonneke A van Vught Judith A Burger Meliawati Poniman Melissa Oomen Dirk Eggink Tom PL Bijl Hugo DG van Willigen Elke Wynberg Bas J Verkaik Orlane JA Figaroa Peter J de Vries Tessel M Boertien Amsterdam UMC COVID-19 S3/HCW study group Marije K Bomers Jonne J Sikkens Roger Le Grand Menno D de Jong Maria Prins Amy W Chung Godelieve J de Bree Rogier W Sanders Marit J van Gils |
| author_facet |
Marloes Grobben Karlijn van der Straten Philip JM Brouwer Mitch Brinkkemper Pauline Maisonnasse Nathalie Dereuddre-Bosquet Brent Appelman AH Ayesha Lavell Lonneke A van Vught Judith A Burger Meliawati Poniman Melissa Oomen Dirk Eggink Tom PL Bijl Hugo DG van Willigen Elke Wynberg Bas J Verkaik Orlane JA Figaroa Peter J de Vries Tessel M Boertien Amsterdam UMC COVID-19 S3/HCW study group Marije K Bomers Jonne J Sikkens Roger Le Grand Menno D de Jong Maria Prins Amy W Chung Godelieve J de Bree Rogier W Sanders Marit J van Gils |
| author_sort |
Marloes Grobben |
| title |
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| title_short |
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| title_full |
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| title_fullStr |
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| title_full_unstemmed |
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| title_sort |
cross-reactive antibodies after sars-cov-2 infection and vaccination |
| publisher |
eLife Sciences Publications Ltd |
| publishDate |
2021 |
| url |
https://doaj.org/article/355bde8c5cd74382bd903bb187245f09 |
| work_keys_str_mv |
AT marloesgrobben crossreactiveantibodiesaftersarscov2infectionandvaccination AT karlijnvanderstraten crossreactiveantibodiesaftersarscov2infectionandvaccination AT philipjmbrouwer crossreactiveantibodiesaftersarscov2infectionandvaccination AT mitchbrinkkemper crossreactiveantibodiesaftersarscov2infectionandvaccination AT paulinemaisonnasse crossreactiveantibodiesaftersarscov2infectionandvaccination AT nathaliedereuddrebosquet crossreactiveantibodiesaftersarscov2infectionandvaccination AT brentappelman crossreactiveantibodiesaftersarscov2infectionandvaccination AT ahayeshalavell crossreactiveantibodiesaftersarscov2infectionandvaccination AT lonnekeavanvught crossreactiveantibodiesaftersarscov2infectionandvaccination AT judithaburger crossreactiveantibodiesaftersarscov2infectionandvaccination AT meliawatiponiman crossreactiveantibodiesaftersarscov2infectionandvaccination AT melissaoomen crossreactiveantibodiesaftersarscov2infectionandvaccination AT dirkeggink crossreactiveantibodiesaftersarscov2infectionandvaccination AT tomplbijl crossreactiveantibodiesaftersarscov2infectionandvaccination AT hugodgvanwilligen crossreactiveantibodiesaftersarscov2infectionandvaccination AT elkewynberg crossreactiveantibodiesaftersarscov2infectionandvaccination AT basjverkaik crossreactiveantibodiesaftersarscov2infectionandvaccination AT orlanejafigaroa crossreactiveantibodiesaftersarscov2infectionandvaccination AT peterjdevries crossreactiveantibodiesaftersarscov2infectionandvaccination AT tesselmboertien crossreactiveantibodiesaftersarscov2infectionandvaccination AT amsterdamumccovid19s3hcwstudygroup crossreactiveantibodiesaftersarscov2infectionandvaccination AT marijekbomers crossreactiveantibodiesaftersarscov2infectionandvaccination AT jonnejsikkens crossreactiveantibodiesaftersarscov2infectionandvaccination AT rogerlegrand crossreactiveantibodiesaftersarscov2infectionandvaccination AT mennoddejong crossreactiveantibodiesaftersarscov2infectionandvaccination AT mariaprins crossreactiveantibodiesaftersarscov2infectionandvaccination AT amywchung crossreactiveantibodiesaftersarscov2infectionandvaccination AT godelievejdebree crossreactiveantibodiesaftersarscov2infectionandvaccination AT rogierwsanders crossreactiveantibodiesaftersarscov2infectionandvaccination AT maritjvangils crossreactiveantibodiesaftersarscov2infectionandvaccination |
| _version_ |
1718416756063600640 |